B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004